Search

NUTLEY, N.J., Nov. 21, 2024 /PRNewswire/ -- Eisai Inc. announced today its sponsorship of the upcoming webinar, 'Lessons Learned from Central Disorders of Hypersomnolence and Future Directions', a key educational [...]

JACKSONVILLE, Fla. -- Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that its third batch of pharmaceutical drug crystals grown in [...]

DANVERS, Mass., Oct. 28, 2024 /PRNewswire/ -- Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported with Impella ECP(TM), a [...]

WINLEVI poster presentations at 2024 Fall Clinical Dermatology Conference also include data affirming reduced acne severity and tolerability in patients with skin of color. MUMBAI, India and PRINCETON, N.J., Oct. [...]

Presentations Include New Data from the TAK-861-2001 Phase 2b Trial in Narcolepsy Type 1 Highlighting Impact on Daily Functioning Including Cognition and Sleep Quality Data from Long-Term Extension Study will [...]

Final results from the DAYBREAK long-term extension study showed brain volume loss decreased during Phase 3 studies and was sustained with continuous Zeposia treatment for up to 5 years More [...]

Research highlights the use of multimodal machine learning to identify non-small cell lung cancer patients predicted to derive the most benefit from combination immunotherapy BOSTON and ROLLE, Switzerland, Sept. 14, [...]

Posters will highlight findings from studies evaluating investigational ND0612 in Parkinson's disease and RADICAVA ORS(edaravone) in ALS JERSEY CITY, N.J., Sept. 12, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. [...]

Pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous RYBREVANT, a three-fold reduction from 67.4 percent historically seen with standard IRR management SAN DIEGO, Sept. 10, 2024 [...]

Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise WILMINGTON, Mass. -- Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the [...]

HYOGO, Japan -- JCR Pharmaceuticals Co., Ltd. (TSE 4552: Chairman and President Shin Ashida, 'JCR') announced presentations highlighting its latest advancements in gene therapy research at the 7th International Forum [...]

Byline: Ariana Eunjung Cha; Rachel Roubein The active compound in the best-selling drug Ozempic markedly lowers the risk of complications from chronic kidney disease, according to a multiyear study published [...]

Conquer Cancer Supports Cancer Research and Education CAMBRIDGE, Mass., June 25, 2024 /PRNewswire/ -- ONO PHARMA USA today announced it will provide a sponsorship to Conquer Cancer, the ASCO Foundation, [...]

Octapharma to present new clinical and scientific findings for wilate and Nuwiq at the upcoming ISTH 2024 Congress New data and clinical study developments to be showcased in seven oral [...]

First presentation of data from Phase 3 KRYSTAL-12 study showed statistically significant and clinically meaningful improvement in progression-free survival with KRAZATI compared to standard of care chemotherapy Late-breaking data featured [...]

Seltorexant, an investigational first-in-class therapy, met all primary and secondary endpoints in pivotal Phase 3 study in patients with major depressive disorder (MDD) with insomnia symptoms, as presented at ASCP [...]

SUZHOU, China and ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related [...]

* Almost 80% of patients with Huntington's disease (HD) chorea were able to achieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results * [...]

NUTLEY, N.J., April 12, 2024 /PRNewswire/ -- Eisai Inc. announced today the Company will present findings from its robust neurology portfolio, including data from the Phase 3 Clarity AD trial [...]

Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official [...]

M2 EQUITYBITES-September 11, 2024-Dupixent shows promise in treating chronic spontaneous urticaria (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US-based biotechnology company Regeneron Pharmaceuticals Inc [...]

M2 EQUITYBITES-July 22, 2024-Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Ionis Pharmaceuticals Inc (NASDAQ: IONS), a provider of RNA-targeted therapies, on Monday [...]

SAN FRANCISCO, March 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS - ADR ADR Class B) who suffered substantial losses to https://www.globenewswire.com/Tracker?data=ZBO-WWcpKCo9irNHzOG6WZQNfOBEGEnZrAtAHzbPMGxcfzSS1O8neCR0WhdVRdiykxiLmYOKhJTIM1uqwgUijrYeG1k5rb1wZQS9U89h9OlrAJ8cqL_J6STCLaxPiUQT. Visit: https://www.globenewswire.com/Tracker?data=KcVrLFO8l401U674PNrrNLmDO2jSDgBy90z2AnceLBi52DPTWk0HYN_Lie6F5qHGKZu52S9_omLOYPbgKZocFpkmBtsAv0nuEA2RzIeKCDmD28aP_VpHqTIVvR2EjeBIp7vQ7_FH6ZzRWdahyvI1pA== [...]

SAN FRANCISCO, March 20, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS - ADR ADR Class B) who suffered substantial losses to https://www.globenewswire.com/Tracker?data=xcJlMFm_v6OfYyoXVDl_Py7F0BxTgQNOevBi3p3mvz6eJJ2rp-0POqFy6TfDB9lzo_9opaUmJ0aOHBt5qksT9zOHzTR6u1zT2bGvvIpCHMHCWIFph00IxF3biA-08Y2J. Visit: https://www.globenewswire.com/Tracker?data=_h_ajkIVqMixs5wVKxJBfMftyfbYhosZOoY3tv9RfVGOocpT3D9mj7TLV10Z4lsLcmG4K6jkgGut1_dff78_1zKoIafVCqYbAPz69HfQqqx6mx1Ck_M3z-RWf98DxJvatv_iyzA1Y_B4ZOYa_KwlMA== [...]

CARLSBAD, Calif. -- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results [...]

ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B [...]

Longer-Term Efficacy and Safety Results from the Phase 3 LEAP-002 Trial Offer Additional Information About the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma Data on E7386 and Tasurgratinib (formerly [...]

- Research Theme: New Strategies to Engage Neurophils in Solid Tumors - OSAKA, Japan, Jan. 9, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan) informed that it has started [...]

M2 EQUITYBITES-June 19, 2024-Medivir anounces selection of global CRO for Phase 2b study in HCC with fostrox + Lenvima (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Pharmaceutical company Medivir AB (NASDAQ: MVIR) (STOCKHOLM: [...]

M2 EQUITYBITES-June 17, 2024-Pfizer announces ELREXFIO (elranatamab-bcmm) Phase 2 MagnetisMM-3 study results in relapsed or refractory multiple myeloma patients (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk US-based pharmaceutical and biotechnology company Pfizer Inc. [...]

M2 EQUITYBITES-May 16, 2024-Ionis and Biogen cease development of BIIB105 for ALS following Phase 1/2 study (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk US biotechnology companies Ionis Pharmaceuticals Inc (Nasdaq:IONS) and Biogen Inc [...]

Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), presents additional results from the [...]

M2 EQUITYBITES-April 8, 2024-Ionis Pharmaceuticals announces phase three Olezarsen Balance study results (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), a United States-based biotechnology company, announced on Sunday full [...]